DXCMDexcom

$84.10+11% 1Y

$84.10

$54.8452 weeks$92.35

Is the price fair?

Fair

The yardsticks disagree: cheap against its own 5-year P/E range (12th percentile) but the cash-flow math implies demanding growth. Treat as fair, not cheap.

2 good, 1 to watch

What the price assumes~+6% a yearderived · Jun 30, 2026

Priced for ~6% a year FCF growth. The price demands less than its three-year revenue growth of 16% a year, expectations look modest.

Vs its own P/E rangecheaper than 88% of its own historyderived

Cheap vs its own history: P/E 33.4 vs a 90.2 median over 26 quarters (−63% vs median).

Vs sector (EV/EBIT)29.7×derived · Dec 31, 2025

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 74% of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What DXCM's price assumes

Dexcom trades at 33.4× earnings against 26.2× for the median Medical Devices name, more expensive than its own group.

33.4

Trailing P/E · Medical Devices median 26.2 · 1.27× the median: the market pays up for this one

Price / sales: 6.00
Price / sales · today's price, fiscal year to Dec 31, 2025
Free cash flow yield: 5.0%
Free cash flow yield · Medical Devices median 4.5%
Growth the price implies: +5.6%
Growth the price implies · The price pays for +5.6% free cash flow growth a year for a decade; the business has delivered +44% a year over the last three.